查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402096

全球臨床腫瘤學下一代定序市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Clinical Oncology Next Generation Sequencing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2030 年，全球臨床腫瘤學下一代定序市場的市場規模將從 2022 年的 421.6 萬美元達到近 1,406.19 萬美元，2023-2030 年研究期間CAGR為 16.25%。

臨床腫瘤學次世代定序（NGS）是指先進的基因組定序技術在腫瘤學（癌症照護和治療）領域的應用。它能夠對患者的腫瘤 DNA 或 RNA 進行全面分析，以識別驅動癌症發生、進展和治療反應的基因改變、突變或變異。

市場動態

下一代定序的技術進步以準確性提高、定序速度更快和成本降低為標誌，推動了其在臨床腫瘤學中的採用。向個人化醫療和精準腫瘤學的範式轉變擴大了其在分析腫瘤遺傳學方面的用途，促進基於個體基因譜的客製化治療策略。全球癌症發生率不斷上升，推動了對 NGS 等先進診斷工具的需求，有助於準確的腫瘤分析和治療決策。 NGS 在癌症研究、識別新生物標記和治療標靶以及推動其涵蓋臨床研究和試驗中也發揮關鍵作用。醫療保健提供者擴大將基於 NGS 的測試涵蓋癌症診斷、預後和治療選擇的常規臨床實踐中。支持性監管環境和既定指南可驗證下一代定序應用，確保臨床環境的品質和可靠性。技術提供者、製藥公司和研究機構之間的夥伴關係和協作促進創新、產品開發和更廣泛地獲得基於 NGS 的腫瘤學測試。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球臨床腫瘤次世代定序市場的各個細分市場進行了包容性評估。臨床腫瘤學下一代定序產業的成長和趨勢為這項研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲臨床腫瘤學下一代定序市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。臨床腫瘤新一代定序市場的主要參與者包括Illumina Inc.、Thermo Fisher Scientific、F. Hoffmann-La Roche Ltd.、Agilent Technologies、Myriad Genetics、北京基因組研究所（BGI）、Perkin Elmer、Foundation Medicine、Pacific Bioscience 、Oxford Nanopore Technologies Ltd.、Paradigm Diagnostics、Caris Life Sciences、Partek Inc.、Eurofins Scientific SE、Qiagen NV 本部分包含競爭格局的整體視圖，其中包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：臨床腫瘤學下一代定序 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按技術分類的市場吸引力分析
    • 依工作流程進行市場吸引力分析
    • 市場吸引力分析：依應用分類
    • 按最終用途分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球臨床腫瘤學下一代定序市場分析：按技術分類

  • 依技術概述
  • 歷史和預測數據
  • 依技術分析
  • 全基因組定序
  • 全外顯子定序
  • 標靶定序和重定序

第 6 章：全球臨床腫瘤學下一代定序市場分析：依工作流程

  • 按工作流程概述
  • 歷史和預測數據
  • 按工作流程分析
  • NGS預測序
  • NGS定序
  • NGS數據分析

第 7 章：全球臨床腫瘤學下一代定序市場分析：按應用分類

  • 概述：按應用
  • 歷史和預測數據
  • 分析：按應用
  • 篩檢（散發性癌症、遺傳性癌症）
  • 伴隨診斷
  • 其他診斷

第 8 章：全球臨床腫瘤學下一代定序市場分析：按最終用途分類

  • 按最終用途分類的概述
  • 歷史和預測數據
  • 按最終用途分析
  • 醫院
  • 診所
  • 實驗室

第 9 章：全球臨床腫瘤學下一代定序市場分析：按地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區國家/地區銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：臨床腫瘤學下一代定序公司的競爭格局

  • 臨床腫瘤學下一代定序市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 公司股份分析
  • 市場集中度
  • Illumina Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Thermo Fisher Scientific
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • F. Hoffmann-La Roche Ltd.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Agilent Technologies
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Myriad Genetics
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Beijing Genomics Institute (BGI)
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Perkin Elmer
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Foundation Medicine
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Pacific Bioscience
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Oxford Nanopore Technologies Ltd.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Paradigm Diagnostics
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Caris Life Sciences
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Partek Inc.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Eurofins Scientific SE
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Qiagen NV
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

Product Code: VMR112112976

The global demand for Clinical Oncology Next Generation Sequencing Market is presumed to reach the market size of nearly USD 1406.19 MN by 2030 from USD 421.6 MN in 2022 with a CAGR of 16.25% under the study period 2023 - 2030.

Clinical oncology next generation sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology (cancer care and treatment). It enables the comprehensive analysis of a patient's tumor DNA or RNA to identify genetic alterations, mutations, or variations that drive cancer development, progression, and response to treatments.

MARKET DYNAMICS

Technological advancements in next generation sequencing, marked by enhanced accuracy, faster sequencing, and reduced costs, drive its adoption in clinical oncology. The paradigm shift towards personalized medicine and precision oncology amplifies its use for analyzing tumor genetics, facilitating tailored treatment strategies based on individual genetic profiles. The escalating incidence of cancer globally fuels the demand for advanced diagnostic tools like NGS, aiding accurate tumor profiling and treatment decisions. NGS also plays a pivotal role in cancer research, identifying new biomarkers and therapeutic targets, and driving its incorporation into clinical studies and trials. Healthcare providers increasingly integrate NGS-based tests into routine clinical practice for cancer diagnosis, prognosis, and treatment selection. Supportive regulatory environments and established guidelines validate next generation sequencing applications, ensuring quality and reliability in clinical settings. Partnerships and collaborations between technology providers, pharmaceutical companies, and research institutions foster innovation, product development, and wider accessibility to NGS-based oncology tests.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of clinical oncology next generation sequencing. The growth and trends of clinical oncology next generation sequencing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the clinical oncology next generation sequencing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing

By Workflow

  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis

By Application

  • Screening (Sporadic Cancer, Inherited Cancer)
  • Companion Diagnostics
  • Other Diagnostics

By End-Use

  • Hospitals
  • Clinics
  • Laboratories

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Clinical Oncology Next Generation Sequencing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Clinical Oncology Next Generation Sequencing market include Illumina Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Caris Life Sciences, Partek Inc., Eurofins Scientific S.E., Qiagen N.V. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Technology
    • 3.7.2 Market Attractiveness Analysis By Workflow
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY TECHNOLOGY

  • 5.1 Overview by Technology
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Technology
  • 5.4 Whole Genome Sequencing Historic and Forecast Sales by Regions
  • 5.5 Whole Exome Sequencing Historic and Forecast Sales by Regions
  • 5.6 Targeted Sequencing & Resequencing Historic and Forecast Sales by Regions

6 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY WORKFLOW

  • 6.1 Overview by Workflow
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Workflow
  • 6.4 NGS Pre-Sequencing Historic and Forecast Sales by Regions
  • 6.5 NGS Sequencing Historic and Forecast Sales by Regions
  • 6.6 NGS Data Analysis Historic and Forecast Sales by Regions

7 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Screening (Sporadic Cancer, Inherited Cancer) Historic and Forecast Sales by Regions
  • 7.5 Companion Diagnostics Historic and Forecast Sales by Regions
  • 7.6 Other Diagnostics Historic and Forecast Sales by Regions

8 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY END-USE

  • 8.1 Overview by End-use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-use
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Clinics Historic and Forecast Sales by Regions
  • 8.6 Laboratories Historic and Forecast Sales by Regions

9 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. South East Asia Sales Analysis
    • 9.5.10. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING COMPANIES

  • 10.1. Clinical Oncology Next Generation Sequencing Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

  • 11.1. Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Illumina Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Thermo Fisher Scientific
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. F. Hoffmann-La Roche Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Agilent Technologies
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Myriad Genetics
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Beijing Genomics Institute (BGI)
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Perkin Elmer
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Foundation Medicine
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Pacific Bioscience
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Oxford Nanopore Technologies Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Paradigm Diagnostics
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Caris Life Sciences
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Partek Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Eurofins Scientific S.E.
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Qiagen N.V.
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Technology (USD MN)
  • Whole Genome Sequencing Market Sales by Geography (USD MN)
  • Whole Exome Sequencing Market Sales by Geography (USD MN)
  • Targeted Sequencing & Resequencing Market Sales by Geography (USD MN)
  • Analysis Market by Workflow (USD MN)
  • NGS Pre-Sequencing Market Sales by Geography (USD MN)
  • NGS Sequencing Market Sales by Geography (USD MN)
  • NGS Data Analysis Market Sales by Geography (USD MN)
  • Analysis by Application (USD MN)
  • Screening (Sporadic Cancer, Inherited Cancer) Market Sales by Geography (USD MN)
  • Companion Diagnostics Market Sales by Geography (USD MN)
  • Other Diagnostics Market Sales by Geography (USD MN)
  • Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Laboratories Market Sales by Geography (USD MN)
  • Global Clinical Oncology Next Generation Sequencing Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Clinical Oncology Next Generation Sequencing Report
  • Market Research Process
  • Market Research Methodology
  • Global Clinical Oncology Next Generation Sequencing Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Technology
  • Market Attractiveness Analysis by Workflow
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by End-use
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Technology (USD MN)
  • Whole Genome Sequencing Market Sales by Geography (USD MN)
  • Whole Exome Sequencing Market Sales by Geography (USD MN)
  • Targeted Sequencing & Resequencing Market Sales by Geography (USD MN)
  • Global Market Analysis by Workflow (USD MN)
  • NGS Pre-Sequencing Market Sales by Geography (USD MN)
  • NGS Sequencing Market Sales by Geography (USD MN)
  • NGS Data Analysis Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Screening (Sporadic Cancer, Inherited Cancer) Market Sales by Geography (USD MN)
  • Companion Diagnostics Market Sales by Geography (USD MN)
  • Other Diagnostics Market Sales by Geography (USD MN)
  • Global Market Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Laboratories Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.